Hepatic Encephalopathy and Chronic Cerebrovascular Dysfunction (synthesis article)
Open Access
- 1 June 2026
- journal article
- Published by State Agency on Intellectual Property in Intellectus
- No. 1,p. 168-180
Abstract
Hepatic encephalopathy (HE) is a frequent and disabling complication of liver cirrhosis and chronic liver failure. While traditionally attributed primarily to hyperammonemia, growing evidence indicates that HE results from the interaction of metabolic disturbances, systemic inflammation, intestinal dysbiosis, and cerebrovascular dysfunction, supporting its reconceptualization as a chronic brain disorder. A narrative review of the international literature published between 2000 and 2025 was conducted using PubMed/Medline, Journal of Hepatology, SpringerLink, and Google Scholar. Human studies relevant to the pathophysiology, diagnosis, and management of hepatic encephalopathy - including randomized controlled trials, observational studies, meta-analyses, and international guidelines - were included and synthesized qualitatively. Contemporary evidence supports an integrative gut-liver-brain model in which hyperammonemia acts synergistically with systemic inflammation, microbiome alterations, and blood-brain barrier dysfunction. These mechanisms converge to induce neuroinflammation, astrocytic dysfunction, and impaired cerebral blood flow autoregulation. Clinically, HE manifests across a broad cognitive, behavioral, and neuromotor spectrum, including minimal and covert forms associated with significant functional impairment. Cerebrovascular dysfunction appears to contribute to persistent cognitive deficits even after metabolic correction. Hepatic encephalopathy should be conceptualized as a metabolic-inflammatory-vascular brain disorder. While established therapies targeting ammonia and precipitating factors remain fundamental, emerging adjunctive approaches aimed at modulating inflammation, microbiome composition, and cerebral microcirculation warrant further investigation within rigorously designed clinical trials.Keywords
This publication has 37 references indexed in Scilit:
- Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple SclerosisHepatology, 2020
- Cholangiocyte‐derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humansHepatology, 2018
- Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trialHepatology, 2017
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverHepatology, 2014
- Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulationHepatology, 2014
- Hepatic encephalopathy in a liver transplant recipient with stable liver functionHepatology, 2013
- OZONE2010
- Bile salt–phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent #Hepatology, 2009
- Identifying the direct effects of ammonia on the brainMetabolic Brain Disease, 2008
- Proteomic profiling of human liver biopsies: Hepatitis C virus–induced fibrosis and mitochondrial dysfunctionHepatology, 2007